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OBJECTIVE — The purpose of this study was to determine whether a strategy of aggressive
cardiovascular risk management reduced the mortality associated with diabetic foot ulceration.
RESEARCH DESIGN AND METHODS — After an initial audit of outcomes demon-
strating a high mortality rate in 404 diabetic foot ulcer patients with the ﬁrst ulceration devel-
oping between 1995 and 1999, a new aggressive cardiovascular risk policy was introduced as
standard practice at the Diabetic Foot Clinic, Royal Inﬁrmary of Edinburgh, in 2001. In the ﬁrst
3yearsofthispolicy,251patientswerescreenedandidentiﬁed.Theauditcyclewasthenclosed
by reauditing the 5-year mortality for this second group of foot ulcer patients in 2008.
RESULTS — Overall5-yearmortalitywasreducedfrom48.0%incohort1to26.8%incohort
2( P  0.001). Improvement in survival was seen for both neuroischemic patients (5-year
mortality of 58% reduced to 36%; relative reduction 38%) and neuropathic patients (36%
reduction to 19%; relative reduction 47%) (both P  0.001). Patients were more likely to die if
they were older at the time of ulceration or had type 2 diabetes, renal impairment, or preexisting
cardiovascular disease or were already taking aspirin. Prior statin use, current smoker or ex-
smoker status, blood pressure, A1C, and total cholesterol were not signiﬁcantly different be-
tween survivors and those who died in the follow-up periods.
CONCLUSIONS — Diabetic foot ulcer patients have a high risk of death. Survival has
improved over the past 13 years. The adoption of an aggressive cardiovascular risk management
policy in diabetic foot ulcer clinics is recommended for these patients.
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L
ower limb amputation in diabetic
patientsisassociatedwithsigniﬁcant
excess mortality (1). Foot ulceration
is also believed to be associated with in-
creased deaths due to related cardiovas-
cular disease (2,3). In addition, patients
with foot ulceration often have advanced
diabetes complications (4). Cardiovascu-
lar risk reduction has, over the last 10
years, become a major part of diabetes
care, particularly for type 2 diabetic pa-
tients. However, it has only been since
2004 that the U.K. General Medical Ser-
vices contract has made the treatment of
cardiovascular risk a renumerated part of
diabetesmanagementinprimarycare(5).
This initiative is driven by target A1C,
blood pressure, and cholesterol levels
rather than absolute or calculated risk as
in the past and has increased prescribing
oftherapiesaimedtoreducecardiovascu-
lar risk (6). Patients without established
risk factors might not receive adequate
treatment if their values are not above the
target.
It is likely that the peripheral arterial
disease and microvascular sclerosis asso-
ciated with diabetic foot ulceration will
reﬂect established arterial disease else-
where in the body (3). Therefore, cardio-
vascular risk factor intervention might be
expected to be effective in this setting.
However, there are no studies of aggres-
sive risk factor modiﬁcation in patients
with diabetic foot ulcer patients to deter-
mine whether such a strategy improves
survival.
RESEARCH DESIGN AND
METHODS— The specialist Diabetic
FootClinicoftheRoyalInﬁrmaryofEdin-
burgh was started, in its current form, in
March 1995. As part of the structure of
the clinic, separate notes, a database, and
robust audit procedures were put in
place. The healing rates and other out-
come results of the ﬁrst 4 years of care in
the clinic have been published elsewhere
(7), but the mortality after foot ulceration
in this group of patients prompted this
audit.
This audit was designed to determine
whether a new policy of standard care,
optimizing cardiovascular risk reduction,
in an identiﬁed high-risk population
would inﬂuence mortality. Two cohorts
of patients were studied. Cohort 1 com-
prised patients referred with new ulcer-
ation between 1 March 1995 and 28
February 1999. Cohort 2 comprised pa-
tients referred between July 2001 and
March 2004. All follow-up was until 31
July 2008.
In each group survival was measured
from the time of the ﬁrst ulceration to
death even if the ﬁrst ulcer occurred be-
fore referral to the clinic. Ulcer type was
determined in the following manner. Pa-
tients with both pedal pulses present
without a history of revascularization
were deemed to be primarily neuro-
pathic; patients with absent pulses or a
prior history of revascularization were
deemed to be neuroischemic.
Whenthemortalityrateforcohort1
was identiﬁed, the initial therapy his-
tory on ﬁrst attendance to the clinic and
all clinic notes and primary care refer-
rals for this group were examined for
drugs known to reduce cardiovascular
risk. These were statin therapy, anti-
platelet agents, ACE inhibitors, and
-blockers (8).
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from the results of the initial audit. All
patients were screened for known cardio-
vascularriskfactorsincludingbloodpres-
sure and serum cholesterol. A1C, total
cholesterol, and serum creatinine results
were taken from the year of ulceration.
The normal range for A1C in the Royal
Inﬁrmary of Edinburgh is up to 6.5%.
When multiple values existed, the mean
value in the year of ﬁrst ulceration was
used. Blood pressures in cohort 2 were
obtained at the clinic during the cardio-
vascular risk assessment process. Sufﬁ-
cient blood pressure data for analysis of
cohort 1 were not available.
A cardiovascular risk score for pa-
tients in cohort 2 was derived using the
UK Prospective Diabetes Study (UKPDS)
risk engine for primary prevention pa-
tients(9).Patientswithknowncardiovas-
cular disease (ischemic heart disease or
stroke)weredeemedtobesecondarypre-
vention patients.
A detailed drug history was taken,
andthefollowingrecommendationswere
made.Allfootulcerpatientsreferredafter
2001 were recommended to receive an
antiplatelet agent (10,11), either 75 mg
aspirin or 75 mg clopidogrel if they were
aspirin intolerant. The only contraindica-
tions to antiplatelet therapy were known
intolerance, a recent history of gastroin-
testinal bleeding, or unexplained anemia.
Warfarin was a relative contraindication.
Statin therapy was recommended for all
patients without a history of statin intol-
eranceand,ifpatientswerealreadytaking
a statin, the dose was recommended to be
optimized to pravastatin or simvastatin at
a minimum dose of 40 mg (11–16).
ACE inhibitors or angiotensin recep-
tor blockers were recommended for all
patients with hypertension, previous car-
diovascular disease, and/or microalbu-
minuria, unless there was known
renovascular disease (11). Again, doses
were maximized if possible. In addition,
-blockers were recommended for all pa-
tientswithexistingcardiovasculardisease
or in whom blood pressure was still un-
controlled despite ACE inhibition. This
was normal practice in 2001 in line with
the ﬁndings of the UKPDS study and the
expectedhighlevelsofcardiovasculardis-
ease and, despite recent controversy, is
still recommended for secondary preven-
tion of cardiovascular events in the 2006
American Diabetes Association standards
of diabetes care (11,17,18). Peripheral
vascular disease was not an absolute con-
traindicationfor-blockade.Letterswere
sent to the primary care team for every
patienttoinformthemoftheclinicpolicy,
screeningprocess,andthereasonsunder-
lying them, whether changes were
thought to be required or not.
In 2004 and 2005 letters were sent to
ensure that the ﬁrst letter had been re-
ceived and that the recommended ther-
apy changes had been made. In addition,
the causes of death for cohort 1 and any
deaths up that point in cohort 2 were de-
termined. The primary care physician for
each patient was sent a letter asking what
causeofdeathwasregisteredonthedeath
certiﬁcate. Death certiﬁcates are unreli-
ablebutarethebestavailableinformation
for cause of death in the absence of post-
mortem examinations (19). Any causes
of deaths after 2005 have been sought
prospectively.
Statistical analyses
Allstatisticalanalyseswereperformedus-
ing SPSS for Windows (version 11.0;
SPSS, Chicago, IL). Between-group com-
parisons were performed using t tests and

2 tests with the Yates correction, de-
pending on the nature of the comparison
and the distribution of the variables. Sta-
tistical signiﬁcance was taken as two-
tailed at the 0.05 level.
RESULTS— There were 404 foot ul-
ceration patients in cohort 1 and 251 in
cohort2.Theircharacteristicsaredetailed
in Table 1. There were no signiﬁcant dif-
ferences in the available data between the
groups other than initial total cholesterol
levels. Over the 13 years of follow-up,
only six patients from cohort 1 have been
completely lost to follow-up with no out-
come data available because of a loss of
case notes during a change in hospital lo-
cation and a later change in hospital com-
puter systems. At least three of these are
known to have died, but the date and
causeofdeathcouldnotbedeterminedas
noprimarycarecontactdetailswereavail-
able. No patients were lost to follow up in
cohort 2.
Major amputations have been per-
formedon11.3%ofcohort1todate.Sur-
vivalwasnotdifferentbetweenthosewith
and without a major amputation (5-year
mortality without amputation 48%, with
amputation 47.8%, NS). Therefore, am-
putation was not used to subdivide the
groupsinsubsequentanalyses.Patientsin
cohort 1 with peripheral vascular disease
had a higher 5-year mortality than those
with mainly neuropathic ulcers (58 vs.
36%, P  0.001).
Calculated 5-year cardiovascular
mortality in cohort 2 was signiﬁcantly
lower than the actual mortality in cohort
2. Mortality for neuropathic patients was
7.5versus19%andforneuroischemicpa-
tients was 9.0 versus 36% (both P 
0.01).
Prescribing of cardiovascular risk–
reducing drugs improved signiﬁcantly by
2003(Table2).However,furtherchanges
wererecommendedformorethanhalfthe
patients. Analysis of the actions by pri-
mary care teams after recommendations
showedthatthesewereactedonin80%
of occasions (P  0.02). The ﬁnal level of
prescribing of statins and antiplatelet
therapy increased to nearly 90% after a
second letter was sent to follow up on the
recommendations (Table 2).
All 251 cohort 2 patients were fol-
lowedto4years.Therelativeriskofdeath
Table 1—Demographic characteristics of the two cohorts
Cohort 1 Cohort 2
n 404 251
Sex (% male) 62 66
Type 2 diabetes (%) 70 77
Age at ﬁrst ulcer (years) 63.2  13.8 61.9  14.9
Mean duration of diabetes (years) 13.4  11.2 13.8  10.8
Ischemic ulcers (%) 52 48
Previous cardiovascular disease (%) 39 36
Current smoker (%) 24 24
Systolic blood pressure (mmHg) — 139.1  23.7
Diastolic blood pressure (mmHg) — 81.7  13.6
A1C 8.6  1.6 8.4  1.8
Creatinine 130 mol/l (%) 22 19
Total cholesterol (mmol/l) 5.21  1.01 4.77  1.30*
Data are means  SD or %. *P  0.05, cohort 1 versus cohort 2.
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Overall mortality at 4 years in cohort 1
was 43.3% and in cohort 2 was 21.9%
(P0.001).Incohort2,160hadanulcer
before 1 August 2003 and their survival
wascomparedwiththe5-yearsurvivalfor
cohort 1. Overall 5-year mortality was re-
duced from 48.0% in cohort 1 to 26.8%
incohort2(P0.001)(Fig.1).Improve-
ment in survival was seen for both neu-
roischemic patients (5-year mortality of
58% reduced to 36%) and neuropathic
patients (mortality of 36% reduced to
19%) (both P  0.001).
Patients in cohort 2 who died were
older at the time of their ﬁrst ulceration
(70.6  10.4 vs. 57.5  15.0 years, P 
0.01) and were more likely to have type 2
diabetes (odds ratio [OR] 3.21 [95% CI
1.53–6.74], P  0.01), renal impairment
(creatinine 130 mol/l) (3.04 [1.57–
5.87]), preexisting cardiovascular disease
(3.25 [1.87–5.67]), or already be taking
aspirin (3.52 [1.93–6.42]). Similar re-
sults were seen in cohort 1. In both co-
hortssex,priorstatinuse,currentsmoker
or ex-smoker status, blood pressure (co-
hort 2 only), A1C, or total cholesterol
were not signiﬁcantly different between
survivors and those who died in the fol-
low-up periods.
The largest single recorded cause of
death in both cohorts was ischemic heart
disease.Ischemicheartdiseasewasthere-
corded cause of death in 61% of cohort 1
and65%ofcohort2patients,withallvas-
cular causes, including stroke, compris-
ing 74 and 81% of deaths, respectively.
Cancer (7%), chronic airway disease
(6%), and end-stage renal failure (5%)
were the next three most prevalent
causes.
The patients in cohort 2 were on av-
erage 1.3 years younger at presentation
(95% CI 	3.5823 to 0.9823, P  0.26).
However, the patients in cohort 2 who
died in the ﬁrst 5 years after presentation
(63 of 87 total deaths to date) were on
average 3.5 years older at death than the
cohort 1 patients who died in the same
period (194 of 285 total deaths to date).
Average age at death in cohort 2 was
73.9  10.1 versus 1 70.4  11.8 years
(P  0.025) in cohort 1.
CONCLUSIONS — This study has
demonstrated improved survival for dia-
betic foot ulcer patients over the past 13
years. The marked improvement in mor-
tality in our patients occurred at a time
when greater attention was given to gly-
cemic control, blood pressure, and lipid
management after publication of the
UKPDS studies and the main lipid stud-
ies of the 1990s (6,10–17,20). However,
oftheavailabledata,onlytotalcholesterol
was signiﬁcantly lower at the time of ul-
ceration in these two groups. Given the
higher levels of blood pressure therapy in
cohort 2, it is likely that blood pressure
would also be lower in this group. How-
ever, extrapolating from the major statin
trials and the UKPDS blood pressure
study, in which the relative risk reduc-
tions for cardiovascular events have been
on the order of 25% and absolute overall
mortality reductions in single ﬁgures,
these differences alone are probably not
enough to explain the difference in mor-
tality between the groups (12–17). Even
the recent study by Charlton et al. (6),
which shows impressive relative reduc-
tions of 37% in early mortality from
type 2 diabetes, reports overall absolute
reductions in mortality of 2%. Other
contemporaneous foot ulcer and amputa-
tion mortality studies still show mortality
rates of 50% at 5 years in a similar dia-
betesandcardiovascularmanagementcli-
mate (1–3). It is therefore likely that the
introduction of the aggressive cardiovas-
cular risk management policy has con-
tributed to the improvement in mortality
observed in these patients.
Thelevelsofdrugtherapyprescribing
in cohort 1 were derived from hospital
case notes and referral letters and may be
an underestimate of the true levels of pre-
scribing, perhaps exaggerating the effect
of the new treatment policy. However,
they are in line with reported aspirin, sta-
tin, and ACE inhibitor use in type 2 dia-
betic patients in 1996 and 2004 (6,10).
Despitethelandmarkstudiesofthe1990s
Table 2—Percent levels of prescribing for major cardiovascular and diabetes drug therapies
on ﬁrst clinic visit in each cohort
Drug therapy Cohort 1 Cohort 2 initial Cohort 2 after letter
Antiplatelet 19 56* 84†
Statin 9.6 54* 88†
ACE inhibitor 8.9 45* 55
Angiotensin receptor blocker 0 5* 6
-Blocker 7 26* 35
Diuretic — 46 —
Insulin — 50 —
Metformin — 36 —
Sulfonylurea — 12 —
*All P  0.05, cohort 2 versus cohort 1. †P  0.05 after follow-up letter versus on presentation to the clinic.
Figure 1—Survival graphs for cohort 1 (Œ) and cohort 2 (F). The 5-year survival of 52.0% in
cohort 1 improved to 73.2% in cohort 2 (P  0.001).
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scription of proven cardiovascular risk–
lowering medications in cohort 2. This
ﬁnding is also in keeping with the gaps in
prescribing in similar studies of therapies
for cardiovascular risk reduction in dia-
betic patients (6,10,21,22). The gaps in
prescribing might be partly explained be-
cause this group of patients was not
widely recognized as being one with a
proven high mortality outside of diabetic
foot care centers nor one in which there
was an evidence base for successful car-
diovascular risk reduction. Even the most
accurate cardiovascular risk modeling
would have seriously underestimated
mortality and, therefore, before universal
treatment recommendations in type 2 di-
abetic patients only those with true sec-
ondary prevention needs would have
been treated and then often incompletely
(6,9,10). The eventual levels of statin and
antiplatelet therapy are signiﬁcantly
higher than those achieved by national
guidelines alone in other studies
(6,10,21,22). This is likely to reﬂect the
fact that the diabetes foot clinic, by focus-
ing care for this high-risk group of pa-
tients and by regular review and follow-
up, is in the best position to ensure that
cardiovascular risk–reducing therapies
are prescribed and used.
The signiﬁcant beneﬁts in mortality
were seen despite blood pressure and to-
tal cholesterol measurements that would
not have merited blanket treatment for
cardiovascular risk according to Quality
and Outcomes Framework or other tar-
get-driven guidelines (5). This result may
be due to additional antiplatelet effects,
ACE inhibition, and the noncholesterol-
related beneﬁts of statin treatment
(11,23).
The association of older age but not
duration of diabetes with risk of dying
would be in keeping with the known
higher mortality in type 2 diabetic pa-
tients (17,20). Preexisting vascular dis-
ease and secondary prevention measures
explain the higher initial levels of aspirin
use in those who died (6,10,11). Risk re-
duction therapy was similar between the
dead and surviving patients after the
changes imposed by the new prescribing
policy. Smoking rates were high in both
groups, and either the overall numbers in
the study were too small to determine a
difference in outcome or diabetes and
other factors had a greater effect. The lack
of a difference in A1C between survivors
and those who died is unsurprising in a
population of only 650 patients. In the
UKPDS study, a difference of 0.9% in
A1C did not signiﬁcantly alter mortality
(20).
The absence of an increase in mortal-
ity after major lower limb amputation is
reassuring and has been reported previ-
ously(24).Itislikelytobetheunderlying
vascular disease in neuroischemic and
neuropathic patients and not the proce-
dure that inﬂuences outcomes. The deci-
sion to group all foot ulcer patients
together was made on the basis of similar
characteristics for the two cohorts and a
high mortality for neuropathic ulcer pa-
tients in this study and in other prospec-
tive studies (25). The beneﬁts of
reduction of cardiovascular mortality
wereseenequallyinbothulcertypes,sug-
gestingthatevenneuropathicdiabeticpa-
tients have a degree of underlying
macrovascular disease.
The relative risk of death within 5
years of foot ulceration was 48.5% lower
in cohort 2 than in cohort 1. The size of
the improvement in mortality and the ob-
servation that this improvement was also
associated with older age at death suggest
that cardiovascular risk reduction treat-
ment does prolong survival in this popu-
lation. The large effect seen in this
population is in keeping with previous
studies, which suggested that absolute
risk reduction is greater in high-risk
groups (12–16,22,23).
The ﬁndings of this study are based
on actual outcomes from a clinic popula-
tion and not a study population. The ad-
vantages of specialist multidisciplinary
foot clinics in improving healing rates for
diabetesfootulcerationandreducingam-
putation rates and hospital admissions
have been described previously, and they
are accepted as the best model of foot ul-
cer care (7). This study adds another jus-
tiﬁcation for concentrating foot ulcer care
in specialist centers. It suggests that spe-
cialist diabetes foot clinics should adopt a
policy of aggressive cardiovascular risk
management, with prescribing of second-
arypreventiontherapiesnotjustforthose
with previously known cardiovascular
events or cholesterol or blood pressure
levels above target but for all foot ulcer
patients.
Acknowledgments— This work was spon-
sored in part by unrestricted research grants
from sanoﬁ-aventis and Bristol-Myers Squibb.
We thank Beth Robertson, podiatrist, for
herworkondatacollectionintheﬁrststagesof
the audit.
References
1. Resnick HE, Carter EA, Lindsay R, Henly
SJ, Ness FK, Welty TK, Lee ET, Howard
BV: Relation of lower-extremity amputa-
tion to all-cause and cardiovascular dis-
ease mortality in American Indians: the
Strong Heart Study. Diabetes Care
27:1286–1293, 2004
2. Moulik PK, Mtonga R, Gill GV: Amputa-
tion and mortality in new-onset diabetic
foot ulcers stratiﬁed by etiology. Diabetes
Care 26:491–494, 2003
3. Ghanassia E, Villon L, Thuan dit Dieud-
onneJ-F,BoegnerC,AvignonA,SultanA:
Long-term outcome and disability of dia-
betic patients hospitalised for diabetic
foot ulcers: a 6.5 year follow-up study.
Diabetes Care 31:1288–1292, 2008
4. Prompers L, Huijberts M, Apelqvist J,
JudeE,PiaggesiA,BakkerK,EdmondsM,
Holstein P, Jirkovska A, Mauricio D, Rag-
narson Tennvall G, Reike H, Spraul M,
Uccioli L, Urbancic V, Van Acker K, van
Baal J, van Merode F, Schaper N: High
prevalence of ischaemia, infection and se-
rious comorbidity in patients with dia-
betic foot disease in Europe: baseline
results from the Eurodiale study. Diabeto-
logia 50:18–25, 2007
5. Quality and outcomes framework: guid-
ance—updated August 2004 [article
online], 2004. Available from www.
paymodernisation.scot.nhs.uk/gms/quality/
docs/QualOutFrame0804.pdf. Accessed
30 June 2008
6. CharltonJ,LatinovicR,GullifordMC:Ex-
plaining the decline in early mortality in
men and women with type 2 diabetes:
population-based cohort study. Diabetes
Care 31:1761–1766, 2008
7. McCormick KG, Young MJ: A clinical au-
dit of the Diabetic Foot Ulcer Clinic. Br J
Podiatry 2:95–96, 1999
8. MacDonald TM, Butler R, Newton RW,
Morris AD: Which drugs beneﬁt diabetic
patients for secondary prevention of myo-
cardial infarction? Diabet Med 15:282–289,
1998
9. Guzder RN, Gatling W, Mullee MA, Mehta
RL Byrne CD: Prognostic value of the Fra-
mingham cardiovascular risk equation and
the UKPDS risk engine for coronary heart
disease in newly diagnosed type 2 diabetes:
results from a United Kingdom study. Dia-
bet Med 22:554–562, 2005
10. CullCA,NeillHAW,HolmanRR.Chang-
ing aspirin use in patients with Type 2
diabetes in the UKPDS: Diabet Med 21:
1368–1371, 2004
11. American Diabetes Association: Position
statement: Standards of medical care in
diabetes–2006.DiabetesCare29:S4–S42,
2006
12. Sacks FM, Pfeffer MA, Moye LA, Rouleau
JL, Rutherford JD, Cole TG, Brown L,
Warnica JW, Arnold JM, Wun CC, Davis
BR,BraunwaldE:Theeffectofpravastatin
Improved survival of diabetic foot ulcer patients
2146 DIABETES CARE, VOLUME 31, NUMBER 11, NOVEMBER 2008on coronary events after myocardial in-
farction in patients with average choles-
terollevels:theCholesterolandRecurrent
Events Trial Investigators. N Engl J Med
335:1001–1009, 1996
13. Long-Term Intervention with Pravastatin
inIschemicDisease(LIPID)StudyGroup:
prevention of cardiovascular events and
death with pravastatin in patients with
coronary heart disease and a broad range
of initial cholesterol levels. N Engl J Med
339:1349–1357, 1998
14. GoldbergRB,MelliesMJ,SacksFM,Moye
LA, Howard BV, Howard WJ, Davis BR,
Cole TG, Pfeffer MA, Braunwald E: Car-
diovascular events and their reduction
with pravastatin in diabetic and glucose-
intolerant myocardial infarction survi-
vors with average cholesterol levels:
subgroup analysis in the Cholesterol
and Recurrent Events (CARE) trial: the
CARE Investigators. Circulation 98:2513–
2519, 1998
15. Haffner SM, Alexander CM, Cook TJ,
Boccuzzi SJ, Musliner TA, Pedersen TR,
Kjekshus J, Pyorala K: Reduced coronary
events in simvastatin-treated patients
with coronary heart disease and diabetes
or impaired fasting glucose levels: sub-
group analyses in the Scandinavian Sim-
vastatin Survival Study. Arch Intern Med
159:2661–2667, 1999
16. Collins R, Armitage J, Parish S, Sleight P,
PetoR,HeartProtectionStudyCollabora-
tive Group: MRC/BHF Heart Protection
Studyofcholesterol-loweringwithsimva-
statinin5963peoplewithdiabetes:aran-
domised placebo-controlled trial. Lancet
361:2005–2016, 2003
17. UK Prospective Diabetes Study Group:
Tight blood pressure control and risk of
macrovascular and microvascular com-
plications in type 2 diabetes: UKPDS 38.
BMJ 317:703–713, 1998
18. Freemantle N, Cleland J, Young P, Mason
J, Harrison J:  Blockade after myocardial
infarction: systematic review and meta re-
gression analysis. BMJ 318:1730–1737,
1999
19. Mu ¨hlhauser I, Sawicki PT, Blank M, Over-
mann H, Richter B, Berger M: Reliability of
causes of death in persons with type I dia-
betes. Diabetologia 45:1490–1497, 2002
20. UK Prospective Diabetes Study (UKPDS)
Group: Intensive blood-glucose control
with sulphonylureas or insulin compared
with conventional treatment and risk of
complications in patients with type 2 di-
abetes(UKPDS33).Lancet352:837–853,
1998
21. Fonarow GC: Statin therapy after acute
myocardial infarction: are we adequately
treating high-risk patients? Curr Athero-
scler Rep 4:99–106, 2002
22. Woodward A, Bayley D, Overend L, Gill
G: Antiplatelet drug use in a diabetic
clinic. Q J Med 100:547–550, 2007
23. Gupta S: Does aggressive statin therapy
offer improved cholesterol-independent
beneﬁts compared to conventional statin
treatment?IntJCardiol96:131–139,2004
24. RamseySD,NewtonK,BloughD,McCul-
loch DK, Sandhu N, Reiber GE, Wagner
EH:Incidence,outcomes,andcostoffoot
ulcers in patients with diabetes. Diabetes
Care 22:382–387, 1999
25. Chammas NK, Hill RL, Foster AV, Ed-
monds ME: Is neuropathic ulceration the
key to understanding increased mortality
due to ischaemic heart disease in diabetic
foot ulcer patients? A population ap-
proach using a proportionate model. J Int
Med Res 30:553–559, 2002
Young and Associates
DIABETES CARE, VOLUME 31, NUMBER 11, NOVEMBER 2008 2147